Definium Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Definium Therapeutics Inc (DFTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Definium Therapeutics Inc vs Its Competitors
- Scale: Definium Therapeutics Inc ranks #1 of 37 companies by market capitalization in the Legal Cannabis industry, holding 38.9% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Definium Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Definium Therapeutics Inc | - | - | - | - |
| Competitors combined (11) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DFTX Stock Performance relative to its Competitors
DFTX Stock Performance relative to High-Confidence Competitors
DFTX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 2 | Compass Pathways Plc | 282.9% | Outperformed |
| 3 | Nrx Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Bright Minds Biosciences Inc | 282.9% | Outperformed |
| 5 | Alzamend Neuro Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Definium Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Definium Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Definium Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Definium Therapeutics Inc | 4,212.66 | - |
| Ataibeckley Inc | 2,651.54 | 4.47 |
| Compass Pathways Plc | 1,679.90 | - |
| Alto Neuroscience Inc | 1,093.02 | - |
| Sage Therapeutics Inc | 543.46 | 70.41 |
| Bright Minds Biosciences Inc | 342.66 | - |
| SUBTOTAL | 10,668.55 | 79.55 |
Sign in to see all competitors of Definium Therapeutics Inc .
Sources: Definium Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Definium Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Definium Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Biohaven Pharmaceutical Holding Co. Ltd. | Named by the company | 85% |
| Jazz Pharmaceuticals | Named by the company | 85% |
| Alkermes Plc | Named by the company | 85% |
| H. Lundbeck A/S | Named by the company | 85% |
| Bristol-Myers Squibb Co. | Named by the company | 85% |
| Otsuka Pharmaceuticals | Named by the company | 85% |
| Biogen | Named by the company | 85% |
| Janssen Pharmaceuticals | Named by the company | 85% |
| Eli Lilly And Co. | Named by the company | 85% |
| Sage Therapeutics | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Definium Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Definium Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Definium Therapeutics Inc | 4,213 | - | - |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Compass Pathways Plc | 1,680 | - | -2,526,840 |
| Alto Neuroscience Inc | 1,093 | - | -1,238,794 |
| Sage Therapeutics Inc | 543 | 199,462 | -853,244 |
| Bright Minds Biosciences Inc | 343 | - | -164,345 |
| PEERS TOTAL | 6,456 | 88,291 | -1,694,263 |
Sign in to see all peers for Definium Therapeutics Inc .
Definium Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 24 companies in Definium Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Definium Therapeutics Inc ranks #1 of 24 companies by market capitalization in its industry, holding 38.89 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,497, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 4,192 | 38.89 % |
| 2 | Regencell Bioscience Holdings Limited | 3,041 | 28.22 % |
| 3 | Cronos Group Inc | 1,238 | 11.48 % |
| 4 | Tilray Brands Inc | 434 | 4.03 % |
| 5 | Canopy Growth Corporation | 1,234 | 5.2% |
| 6 | Sndl Inc | 1,234 | 5.2% |
| 7 | Usana Health Sciences Inc | 1,234 | 5.2% |
| 8 | Niagen Bioscience Inc | 1,234 | 5.2% |
| 9 | Aurora Cannabis Inc | 1,234 | 5.2% |
| 10 | Mediwound Ltd | 1,234 | 5.2% |
Market cap and industry share for the rest of Definium Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Definium Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 4,192 | 214.53 % |
| 2 | Regencell Bioscience Holdings Limited | 3,041 | -62.48 % |
| 3 | Cronos Group Inc | 1,234 | 12.3% |
| 4 | Tilray Brands Inc | 1,234 | 12.3% |
| 5 | Canopy Growth Corporation | 1,234 | 12.3% |
| 6 | Sndl Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Definium Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Definium Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Legal Cannabis industry average (36 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Legal Cannabis industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 18.3x | - |
| EV / EBITDA | - | 7.2x | - |
| P/B | 8.7x | 5.5x | +3.2x |
| Return on Equity | -85.23 % | industry aggregate | -62.02 % |
| Return on Invested Capital | - | 3.29 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Definium Therapeutics Inc's BCG Growth-Share Matrix
Relative market share (vs Definium Therapeutics Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Definium Therapeutics Inc falls in the Cash Cow quadrant: relative market share of 1.38x vs its largest competitor, in an industry growing revenue 2.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Definium Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 2,497 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Definium Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Definium Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Definium Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Definium Therapeutics Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Definium Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Market leader by capitalization in its industry (#1 of 24, 38.89 % share).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 62.0 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Definium Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Compass Pathways Plc | 1.28 | 1.47 | 0.48 |
| Alto Neuroscience Inc | 16.39 | 16.63 | 0.11 |
| Sage Therapeutics Inc | 1.30 | 8.83 | - |
| Bright Minds Biosciences Inc | 35.50 | 36.10 | - |
Sign in to see all peers for Definium Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Definium Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| Alto Neuroscience Inc | Q2 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | +265.8 % | - |
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
| PEERS TOTAL | +261.8 % | - |
Sign in to see all peers for Definium Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Definium Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| Alto Neuroscience Inc | Q2 2026 | - | - |
| Sage Therapeutics Inc | Q2 2025 | - | - |
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
Sign in to see all peers for Definium Therapeutics Inc .
Definium Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Definium Therapeutics Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
| Alto Neuroscience Inc | - | - | - |
| Sage Therapeutics Inc | - | - | - |
| Bright Minds Biosciences Inc | - | - | - |
Sign in to see all peers for Definium Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Definium Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Definium Therapeutics Inc | - | - |
| Ataibeckley Inc | - | 592.79 |
| Compass Pathways Plc | - | - |
| Alto Neuroscience Inc | - | - |
| Sage Therapeutics Inc | - | 7.72 |
| Bright Minds Biosciences Inc | - | - |
| PEERS AVERAGE | - | 134.11 |
Sign in to see all peers for Definium Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.